Pulmonary Hypertension-Associated Right Ventricular Cardiomyocyte Remodelling Reduces Treprostinil Function

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2023 Dec 9

PMID 38067192

Authors

Aleksandra Judina

Marili Niglas

Vladislav Leonov

Nicholas S Kirkby

Ivan Diakonov

Peter T Wright

Lan Zhao

Jane A Mitchell

Julia Gorelik

Affiliations

Soon will be listed here.

Abstract

(1) Pulmonary hypertension (PH)-associated right ventricular (RV) failure is linked to a reduction in pulmonary vasodilators. Treprostinil has shown effectiveness in PAH patients with cardiac decompensation, hinting at potential cardiac benefits. We investigated treprostinil's synergy with isoprenaline in RV and LV cardiomyocytes. We hypothesised that disease-related RV structural changes in cardiomyocytes would reduce contractile responses and cAMP/PKA signalling activity. (2) We induced PH in male Sprague Dawley rats using monocrotaline and isolated their ventricular cardiomyocytes. The effect of in vitro treprostinil and isoprenaline stimulation on contraction was assessed. FRET microscopy was used to study PKA activity associated with treprostinil stimulation in AKAR3-NES FRET-based biosensor-expressing cells. (3) RV cells exhibited maladaptive remodelling with hypertrophy, impaired contractility, and calcium transients compared to control and LV cardiomyocytes. Combining treprostinil and isoprenaline failed to enhance inotropy in PH RV cardiomyocytes. PH RV cardiomyocytes displayed an aberrant contractile behaviour, which the combination treatment could not rectify. Finally, we observed decreased PKA activity in treprostinil-treated PH RV cardiomyocytes. (4) PH-associated RV cardiomyocyte remodelling reduced treprostinil sensitivity, inotropic support, and impaired relaxation. Overall, this study highlights the complexity of RV dysfunction in advanced PH and suggests the need for alternative therapeutic strategies.

References

Bhatnagar A, Wiesen J, Dweik R, Chaisson N . Evaluating suspected pulmonary hypertension: A structured approach. Cleve Clin J Med. 2018; 85(6):468-480. DOI: 10.3949/ccjm.85a.17065. View

Chang K, Duval S, Badesch D, Bull T, Chakinala M, De Marco T . Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry. J Am Heart Assoc. 2022; 11(9):e024969. PMC: 9238604. DOI: 10.1161/JAHA.121.024969. View

Gabriel-Costa D . The pathophysiology of myocardial infarction-induced heart failure. Pathophysiology. 2018; 25(4):277-284. DOI: 10.1016/j.pathophys.2018.04.003. View

Mentz P, Mest H, Anger H . Interaction of iloprost and indomethacin with the cardiac effects of isoprenaline, ouabain and trapidil. Biomed Biochim Acta. 1988; 47(10-11):S109-12. View

Ashek A, Spruijt O, Harms H, Lammertsma A, Cupitt J, Dubois O . 3'-Deoxy-3'-[18F]Fluorothymidine Positron Emission Tomography Depicts Heterogeneous Proliferation Pathology in Idiopathic Pulmonary Arterial Hypertension Patient Lung. Circ Cardiovasc Imaging. 2018; 11(8):e007402. DOI: 10.1161/CIRCIMAGING.117.007402. View

McLaughlin V, Shillington A, Rich S . Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002; 106(12):1477-82. DOI: 10.1161/01.cir.0000029100.82385.58. View

Santos-Ribeiro D, Mendes-Ferreira P, Maia-Rocha C, Adao R, Leite-Moreira A, Bras-Silva C . Pulmonary arterial hypertension: Basic knowledge for clinicians. Arch Cardiovasc Dis. 2016; 109(10):550-561. DOI: 10.1016/j.acvd.2016.03.004. View

Domanski M, Krause-Steinrauf H, Massie B, Deedwania P, Follmann D, Kovar D . A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail. 2003; 9(5):354-63. DOI: 10.1054/s1071-9164(03)00133-7. View

Allen M, Zhang J . Subcellular dynamics of protein kinase A activity visualized by FRET-based reporters. Biochem Biophys Res Commun. 2006; 348(2):716-21. DOI: 10.1016/j.bbrc.2006.07.136. View

10.

Wright P, Nikolaev V, OHara T, Diakonov I, Bhargava A, Tokar S . Caveolin-3 regulates compartmentation of cardiomyocyte beta2-adrenergic receptor-mediated cAMP signaling. J Mol Cell Cardiol. 2013; 67:38-48. PMC: 4266930. DOI: 10.1016/j.yjmcc.2013.12.003. View

11.

Kondo T, Okumura N, Adachi S, Murohara T . ＜Editors' Choice＞ Pulmonary Hypertension: Diagnosis, Management, and Treatment. Nagoya J Med Sci. 2019; 81(1):19-30. PMC: 6433622. DOI: 10.18999/nagjms.81.1.19. View

12.

Bedioune I, Lefebvre F, Lechene P, Varin A, Domergue V, Kapiloff M . PDE4 and mAKAPβ are nodal organizers of β2-ARs nuclear PKA signalling in cardiac myocytes. Cardiovasc Res. 2018; 114(11):1499-1511. PMC: 6106106. DOI: 10.1093/cvr/cvy110. View

13.

Turker R . Evidence for a prostacyclin-mediated chronotropic effect of angiotensin II in the isolated cat right atria. Eur J Pharmacol. 1982; 83(3-4):271-5. DOI: 10.1016/0014-2999(82)90260-6. View

14.

Schobesberger S, Wright P, Tokar S, Bhargava A, Mansfield C, Glukhov A . T-tubule remodelling disturbs localized β2-adrenergic signalling in rat ventricular myocytes during the progression of heart failure. Cardiovasc Res. 2017; 113(7):770-782. PMC: 5437368. DOI: 10.1093/cvr/cvx074. View

15.

Mercurio V, Pellegrino T, Bosso G, Campi G, Parrella P, Piscopo V . EXPRESS: Cardiac Sympathetic Dysfunction in Pulmonary Arterial Hypertension: Lesson from Left-sided Heart Failure. Pulm Circ. 2019; :2045894019868620. PMC: 6689920. DOI: 10.1177/2045894019868620. View

16.

Geraci M, Gao B, SHEPHERD D, Moore M, Westcott J, Fagan K . Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J Clin Invest. 1999; 103(11):1509-15. PMC: 408370. DOI: 10.1172/JCI5911. View

17.

Zhao L, Oliver E, Maratou K, Atanur S, Dubois O, Cotroneo E . The zinc transporter ZIP12 regulates the pulmonary vascular response to chronic hypoxia. Nature. 2015; 524(7565):356-60. PMC: 6091855. DOI: 10.1038/nature14620. View

18.

Schermuly R, Kreisselmeier K, Ghofrani H, Samidurai A, Pullamsetti S, Weissmann N . Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension. Circ Res. 2004; 94(8):1101-8. DOI: 10.1161/01.RES.0000126050.41296.8E. View

19.

Barst R, Rubin L, Long W, McGoon M, Rich S, Badesch D . A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996; 334(5):296-301. DOI: 10.1056/NEJM199602013340504. View

20.

Zhang J, Lu T, Stolerman L, Tenner B, Yang J, Zhang J . Phase Separation of a PKA Regulatory Subunit Controls cAMP Compartmentation and Oncogenic Signaling. Cell. 2020; 182(6):1531-1544.e15. PMC: 7502557. DOI: 10.1016/j.cell.2020.07.043. View